Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.73), $0.06 better than the analyst estimate of ($1.79). Revenue for the quarter came in at $16.3 million versus the consensus estimate of $13.65 million.

“This last year was important for Ultragenyx as we successfully launched two therapies internationally and validated clinical data from our gene therapy platform,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. “In 2019 we look forward to expanding the global commercial reach of our approved therapies, submitting a New Drug Application for a third, and advancing our gene therapy platform toward pivotal studies.”

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.